Clincosm LogoSign in Get a demo

Study on Clinical Features, Treatment Mode and Survival of Sarcoma

Sponsor
Henan Cancer Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05453409
Collaborator
(none)
6,000
Enrollment
1
Location
16.8
Anticipated Duration (Months)
357.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The clinical data of all eligible patients who received chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy and surgery in Henan Tumor Hospital from June 1, 2012 to May 30, 2022 were retrospectively collected.

Condition or Disease Intervention/Treatment Phase
  • Other: No intervention

Detailed Description

This study was a single-center retrospective clinical study, which retrospectively collected the clinical data of all eligible patients receiving chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy and surgical treatment in Henan Tumor Hospital from June 1, 2012 to May 30, 2022. The efficacy, recurrence and survival of various treatments were collected.

Study Design

Study Type:
Observational
Anticipated Enrollment :
6000 participants
Observational Model:
Case-Only
Time Perspective:
Retrospective
Official Title:
A Single-center Retrospective Study of Clinical Features, Treatment Patterns, and Survival of Sarcomas
Actual Study Start Date :
Jun 7, 2022
Anticipated Primary Completion Date :
Oct 31, 2023
Anticipated Study Completion Date :
Oct 31, 2023

Outcome Measures

Primary Outcome Measures

  1. Progression-free survival [Up to approximately 24months]

    Progression-free survival is defined as time from enrollment to the first occurrence of progression of disease or death from any cause within 63 days of last response assessment.

  2. Overall survival [Up to approximately 120months]

    Time from pathological diagnosis to death

Eligibility Criteria

Criteria

Ages Eligible for Study:
6 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

No age limit, male or female. A certain subtype of sarcoma was diagnosed by pathology in our hospital. Has received at least one hospitalization in this hospital. Target lesions can be evaluated according to solid tumor efficacy evaluation criteria (RECIST; Version 1.1) Measure diameter changes.

Complete follow-up data.

Exclusion Criteria:

No clear pathology. Incomplete follow-up data.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Bone and Soft Tissue ,Henan Cancer Hospital Zhengzhou Henan China 450008

Sponsors and Collaborators

  • Henan Cancer Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Wang Jiaqiang, Associate chief physician, Henan Cancer Hospital
ClinicalTrials.gov Identifier:
NCT05453409
Other Study ID Numbers:
  • ZZUSC-11
First Posted:
Jul 12, 2022
Last Update Posted:
Jul 14, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Sarcoma

Study Results

No Results Posted as of Jul 14, 2022